Get the latest Spero Therapeutics, Inc. (SPRO) stock news and headlines to help you in your trading and investing decisions.

The FDA's decision not to approve Spero Therapeutics' oral antibiotic tebipenem Hbr for adults with complicated urinary tract infections (cUTI) further increases the threat of antibiotic ...

GSK is paying $66 million upfront to license rights to Spero Therapeutics novel antibiotic tebipenem Hbr, unswayed by the FDA's decision earlier this year not to approve the drug for adults with ...

Find the latest on short interest, settlement dates, average share volume, and days to cover for Spero Therapeutics, Inc. Common Stock (SPRO) at Nasdaq.com.